Abstract:Background: The development of diabetic retinopathy (DR) is incompletely understood. Administered retinylamine is stored in the retinal pigmented epithelium (RPE) where it affects the ocular visual cycle. Results: Retinylamine inhibited vascular and neural lesions of early DR. Conclusion: Both the RPE and visual cycle are novel targets for the inhibition of DR. Significance: Vision-related processes can contribute to DR.Recent evidence suggests an important role for outer retinal cells in the pathogenesis of diabetic retinopathy (DR). Here we investigated the effect of the visual cycle inhibitor retinylamine (Ret-NH2) on the development of early DR lesions. Wild-type (WT) C57BL/6J mice (male, 2 months old when diabetes was induced) were made diabetic with streptozotocin, and some were given Ret-NH2 once per week. Lecithin-retinol acyltransferase (LRAT)-deficient mice and P23H mutant mice were similarly studied. Mice were euthanized after 2 (WT and Lrat(-/-)) and 8 months (WT) of study to assess vascular histopathology, accumulation of albumin, visual function, and biochemical and physiological abnormalities in the retina. Non-retinal effects of Ret-NH2 were examined in leukocytes treated in vivo. Superoxide generation and expression of inflammatory proteins were significantly increased in retinas of mice diabetic for 2 or 8 months, and the number of degenerate retinal capillaries and accumulation of albumin in neural retina were significantly increased in mice diabetic for 8 months compared with nondiabetic controls. Administration of Ret-NH2 once per week inhibited capillary degeneration and accumulation of albumin in the neural retina, significantly reducing diabetes-induced retinal superoxide and expression of inflammatory proteins. Superoxide generation also was suppressed in Lrat(-/-) diabetic mice. Leukocytes isolated from diabetic mice treated with Ret-NH2 caused significantly less cytotoxicity to retinal endothelial cells ex vivo than did leukocytes from control diabetics. Administration of Ret-NH2 once per week significantly inhibited the pathogenesis of lesions characteristic of early DR in diabetic mice. The visual cycle constitutes a novel target for inhibition of DR.

Intravitreal Administration of AAV2-SIRT1 Reverses Diabetic Retinopathy in a Mouse Model of Type 2 Diabetes

Intravitreally Administered Soluble VEGF Receptor-1 Variant Tested as a Potential Gene Therapeutic for Diabetic Retinopathy

Rescue of retinal ganglion cells in optic nerve injury using cell-selective AAV mediated delivery of SIRT1

Intravitreal injection of adenosine A2A receptor antagonist reduces neuroinflammation, vascular leakage and cell death in the retina of diabetic mice

Therapeutic Delivery of Soluble Fractalkine Ameliorates Vascular Dysfunction in the Diabetic Retina

An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1

Subretinal Delivery of AAV2-Mediated Human Erythropoietin Gene is Protective and Safe in Experimental Diabetic Retinopathy

AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma

Effects of Antioxidant Gene Therapy on the Development of Diabetic Retinopathy and the Metabolic Memory Phenomenon

Administration of pigment epithelium-derived factor delivered by adeno-associated virus inhibits blood-retinal barrier breakdown in diabetic rats.

Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse

AAV2-PDE6B restores retinal structure and function in the retinal degeneration 10 mouse model of retinitis pigmentosa by promoting phototransduction and inhibiting apoptosis

Adeno-Associated Virus Mediated Sod Gene Therapy Protects the Retinal Ganglion Cells from Chronic Intraocular Pressure Elevation Induced Injury Via Attenuating Oxidative Stress and Improving Mitochondrial Dysfunction in A Rat Model

AAV2 vector optimization for retinal ganglion cell-targeted delivery of therapeutic genes

Influence of rAAV-mediated antisense vascular endothelial growth factar165 RNA(rAAV-aVEGF 165) on diabetic retinopathy

SIRT1 is Required for the Neuroprotection of Resveratrol on Retinal Ganglion Cells after Retinal Ischemia-Reperfusion Injury in Mice

Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats.

Retinylamine Benefits Early Diabetic Retinopathy in Mice*

Fractalkine isoforms differentially regulate microglia-mediated inflammation and enhance visual function in the diabetic retina

Long-term RNA Interference Gene Therapy in a Dominant Retinitis Pigmentosa Mouse Model

Overexpression of histone deacetylase SIRT1 exerts an antiangiogenic role in diabetic retinopathy via miR-20a elevation and YAP/HIF1α/VEGFA depletion